Olema Pharmaceuticals, Inc.
OLMA · United States
Share price · OLMA
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when OLMA's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 11 Nov 2026+10.6%
- 6 Nov 2026+8.4%
Nothing announced by OLMA that day or the session before.
- 23 Oct 2026-8.7%
Nothing announced by OLMA that day or the session before.
- 19 Oct 2026+8.1%
Nothing announced by OLMA that day or the session before.
- 11 Aug 2026-12.6%
- 16 Jun 2026-7.0%
Nothing announced by OLMA that day or the session before.
- 2 Jun 2026-15.9%
- 16 Mar 2026+12.8%
- 9 Mar 2026-25.8%
Nothing announced by OLMA that day or the session before.
- 18 Nov 2025+136.4%
Share of unusual movement by asset
For each asset, the share of OLMA's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(2 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | Estrogen receptorSmall molecule | Breast Cancer HR+/HER2- Metastatic Breast Cancer | |
| Phase 1 | KAT6A / KAT6BSmall molecule | Non-Small Cell Lung CancerBreast Cancer HR+/HER2- Metastatic Breast Cancer |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2028 (1)
December 2028 (1)
What to watch
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | — | $68M | $48M+ $366M short-term inv. | $74M-$47M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | — | $58M | $49M+ $412M short-term inv. | $63M-$46M operating cash flow | report ↗ |
| 2026-Q1 | — | $49M | $53M+ $453M short-term inv. | $53M-$46M operating cash flow | report ↗ |
| 2025-Q3 | — | $40M | $35M+ $294M short-term inv. | $42M-$35M operating cash flow | report ↗ |
| 2025-Q2 | — | $44M | $52M+ $309M short-term inv. | $44M-$30M operating cash flow | report ↗ |
| 2025-Q1 | — | $31M | $51M+ $342M short-term inv. | $30M-$44M operating cash flow | report ↗ |
| 2024-Q3 | — | $33M | $36M+ $179M short-term inv. | $35M-$27M operating cash flow | report ↗ |
| 2024-Q2 | — | $29M | $17M+ $222M short-term inv. | $30M-$28M operating cash flow | report ↗ |
| 2024-Q1 | — | $30M | $34M+ $215M short-term inv. | $31M-$24M operating cash flow | report ↗ |
| 2023-Q3 | — | $19M | $117M+ $159M short-term inv. | $22M-$23M operating cash flow | report ↗ |
| 2023-Q2 | — | $18M | $35M+ $132M short-term inv. | $20M-$22M operating cash flow | report ↗ |
| 2023-Q1 | — | $23M | $41M+ $145M short-term inv. | $28M-$20M operating cash flow | report ↗ |
| 2022-Q3 | — | $18M | $27M+ $196M short-term inv. | $23M-$18M operating cash flow | report ↗ |
| 2022-Q2 | — | $27M | $25M+ $216M short-term inv. | $33M-$26M operating cash flow | report ↗ |
| 2022-Q1 | — | $16M | $22M+ $246M short-term inv. | $23M-$18M operating cash flow | report ↗ |
| 2021-Q3 | — | $13M | $26M+ $280M short-term inv. | $18M-$12M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | — | $158M | $48M+ $457M short-term inv. | $41M-$147M operating cash flow | report ↗ |
For full-year 2025, Olema Pharmaceuticals did not disclose revenue, while R&D spend was $157.7M, up 26.6% YoY from $124.52M. The company ended the year with cash and equivalents of $48.3M and cash, equivalents, and marketable securities of $505.4M, and reported a net loss of $162.45M.
The company expects top-line data from the pivotal Phase 3 OPERA-01 trial of palazestrant in the fall of 2026, with initial clinical data from the OP-3136 Phase 1 study expected in Q2 2026 and a potential first commercial launch in late 2027. During the year, enrollment advanced in the OPERA-02 Phase 3 trial, a Phase 1b/2 study of palazestrant with atirmociclib was initiated, and a follow-on public offering generated approximately $218.5M in gross proceeds to strengthen the balance sheet.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | — | $125M | $139M+ $295M short-term inv. | $32M-$104M operating cash flow | report ↗ |
| 2023-FY | — | $86M | $69M+ $193M short-term inv. | $24M-$84M operating cash flow | report ↗ |
| 2022-FY | — | $82M | $24M+ $181M short-term inv. | $26M-$82M operating cash flow | report ↗ |
| 2021-FY | — | $51M | $14M+ $273M short-term inv. | $18M-$51M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases ($0), 25 sales ($24.7M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-09-01 | O'Byrne Jason · CHIEF FINANCIAL OFFICER | Award / grant (derivative) | 650,000 | — | — | Form 4 |
| 2026-07-24 | Harmon Cyrus · director | Open-market sale | 12,500 | $11.71 | $146K | Form 4 |
| 2026-07-23 | Harmon Cyrus · director | Open-market sale | 12,500 | $11.58 | $145K | Form 4 |
| 2026-06-18 | Graham G. Walmsley · director | Award / grant (derivative) | 29,500 | — | — | Form 4 |
| 2026-06-18 | RAPPAPORT ANDREW · director | Award / grant (derivative) | 29,500 | — | — | Form 4 |
| 2026-06-18 | Raman Prakash · director | Award / grant (derivative) | 29,500 | — | — | Form 4 |
| 2026-06-18 | Horning Sandra · director | Award / grant (derivative) | 29,500 | — | — | Form 4 |
| 2026-06-18 | Larson Yi · director | Award / grant (derivative) | 29,500 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 195 reporting institutions held 101.5M shares ($1.5B, 115.8% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | FMR LLC | 10,386,845 | $154.9M |
| 2 | Paradigm Biocapital Advisors LP | 8,020,576 | $119.6M |
| 3 | Bain Capital Life Sciences Investors, LLC | 7,473,238 | $111.4M |
| 4 | JANUS HENDERSON GROUP PLC | 7,108,488 | $106.0M |
| 5 | BlackRock, Inc. | 5,652,135 | $84.3M |
| 6 | BVF INC/IL | 5,295,893 | $79.0M |
| 7 | Siren, L.L.C. | 4,756,949 | $70.9M |
| 8 | STATE STREET CORP | 3,937,831 | $58.7M |
| 9 | Cormorant Asset Management, LP | 3,900,000 | $58.1M |
| 10 | Logos Global Management LP | 3,208,875 | $47.8M |
| 11 | VANGUARD CAPITAL MANAGEMENT LLC | 3,083,517 | $46.0M |
| 12 | RA CAPITAL MANAGEMENT, L.P. | 2,600,000 | $38.8M |
| 13 | JENNISON ASSOCIATES LLC | 1,822,123 | $27.2M |
| 14 | Polar Capital Holdings Plc | 1,602,970 | $23.9M |
| 15 | GEODE CAPITAL MANAGEMENT, LLC | 1,544,417 | $23.0M |